







2021 – significant year for Sanofi's pipeline ahead

Pipeline charts as
communicated at Q3 2020
Results Meeting dated
October 29, 2020

Expected pivotal results⁽¹⁾

- Amcenestrant (AMEERA-3) 2L/3L in mBC 
- Fitusiran for Hemophilia A & B 
- BIVV001⁽²⁾ for Hemophilia A 
- Dupixent[®] for CSU & PN 
- Sarclisa[®] 1L Ti MM (IMROZ)
- Libtayo[®] 1L NSCLC with CT
- COVID-19 vaccine candidates
- Rilzabrutinib in Pemphigus *New*

Expected Phase 2 readouts⁽¹⁾

- Venglustat GBA PD 
- Sarclisa[®] subcutaneous formulation
- Amcenestrant, early BC, AMEERA-4 

 Priority assets

Pipeline programs represent assets under investigation and are not approved by regulators for the uses being investigated.

mBC: metastatic breast cancer; CSU: chronic spontaneous urticaria; PN: prurigo nodularis; 1L Ti MM: first line transplant ineligible multiple myeloma; NSCLC: non-small cell lung cancer; CT: chemotherapy; GBA PD: Parkinson's disease associated with GBA mutation

(1) Represents select molecule highlights; not comprehensive

(2) In collaboration with Sobi